Dupilumab normalizes correlates of lysosomal function in atopic dermatitis
Abstract Background Atopic dermatitis (AD) is characterized by skin barrier dysfunction and immune dysregulation. Autophagy, which is important for the epidermal differentiation, is impaired in AD. The treatment with dupilumab, an interleukin (IL)‐4/IL‐13 receptor blocker, has been shown to reduce s...
Saved in:
Main Authors: | Christina Bürgler (Author), Danielle Dutoit (Author), Susanne Radonjic‐Hoesli (Author), Kathrin Thormann (Author), Mathias Lehmann (Author), Shida Yousefi (Author), Hans‐Uwe Simon (Author), Dagmar Simon (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Experience with dupilumab in patients with atopic dermatitis
by: E. A. Glukhova, et al.
Published: (2023) -
The role of nurses in the management of atopic dermatitis: Results of an international survey
by: Hélène Aubert, et al.
Published: (2022) -
Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy
by: Danielle M. Peterson, MD, et al.
Published: (2021) -
Efficacy of dupilumab in moderate and severe atopic dermatitis
by: Stephan Weidinger, et al.
Published: (2023) -
Dupilumab in the Treatment of Cheilitis in Atopic Dermatitis Patients
by: Shan J, et al.
Published: (2022)